Lynch & Associates IN Invests $1.17 Million in Gilead Sciences, Inc. (GILD)

Lynch & Associates IN bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 14,425 shares of the biopharmaceutical company’s stock, valued at approximately $1,169,000.

Other hedge funds have also made changes to their positions in the company. Penserra Capital Management LLC raised its stake in shares of Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the period. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $147,000. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Gilead Sciences by 29.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $153,000. Finally, Capstone Investment Advisors Netherlands B.V. acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $172,000. 76.23% of the stock is owned by institutional investors and hedge funds.

In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total value of $6,054,372.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 494,999 shares of company stock valued at $37,404,139. 1.30% of the stock is owned by company insiders.

Several research analysts have recently weighed in on GILD shares. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Deutsche Bank reiterated a “buy” rating and set a $81.00 price target on shares of Gilead Sciences in a research report on Thursday, August 31st. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a research report on Thursday, August 31st. Berenberg Bank set a $86.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, August 29th. Finally, Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target for the company. in a research report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $85.11.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $75.57 on Friday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of $97,108.04, a price-to-earnings ratio of 7.76, a price-to-earnings-growth ratio of -1.25 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.75 EPS. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.75%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.69%.

ILLEGAL ACTIVITY WARNING: This story was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://stocknewstimes.com/2017/12/17/lynch-associates-in-invests-1-17-million-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply